Showing all posts written by Benjamin Ho
Benjamin attended college at New York University, where he graduated with degrees in both Computer Science and Economics. He received his Juris Doctor from Cornell Law School, where he was Managing Editor of the Journal of Law and Public Policy.
Benjamin worked as a summer associate at the firm in 2016 and joined the firm in 2017.
The U.S. Food and Drug Administration (FDA) recently authorized 23andMe to market its Personal Genome Service Genetic Health Risk Report for BRCA1/BRCA2 (Selected Variants). According to an FDA news release, the approved test is the
Akili Interactive recently announced results of a trial on the company’s digital medicine product, AKL-T01. According to FierceBiotech, Akili plans to file AKL-T01 with the U.S. Food and Drug Administration (FDA) for clearance